- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05467267
Personalized Urine Biomarker for Patients With Bladder Cancer
Personalized Urine Biomarker for Patients With Bladder Cancer: Pilot Study
Introduction
Bladder cancer is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide. Urothelial carcinoma is accounts for approximately 90 percent of bladder cancers in the western world.
In the United States, approximately 80,000 new cases and 17,000 deaths occur each year due to bladder cancer.
Approximately 75% of patients present with superficial disease (Ta and T1), while 25% present with muscle invasive (T2 or greater) disease. Overall, 70% of treated tumors recur, with 30% of recurrent tumors progressing to muscle invasive disease.
The majority of these patients have a recurrence after endoscopic resection, thus lifelong surveillance with periodically cystoscopy is recommended. Cystoscopy, which is the "gold standard" for the detection of bladder cancer, is an expensive and invasive procedure, and it also can miss a flat lesion, especially carcinoma in situ which is considered a high grade malignant condition, therefore better follow-up tools should be developed in order to address those issues.
Voided urinary cytology is a useful noninvasive adjunct to cystoscopy due to its high specificity, more than 90%. Although it has a high sensitivity at detecting high-grade lesions, between 80 to 90%,, in low-grade its sensitivity is very low, between 20 to 50%. Amongst the non-muscle-invasive, low grade tumors will progress to muscle-invasive or metastatic cancer at approximately 10% and roughly a third of high-grade tumors progress, therefore, close monitoring and early detection of all lesions are important for management, and noninvasive tumor markers with high accuracy for the detection of all grades of urothelial carcinoma will significantly reduce patient cost, anxiety and morbidity.
Cystoscopy in combination with cytology remains the most effective means of detecting bladder cancer. However, cystoscopy is an invasive procedure, and while cytology remains a useful method for detecting high grade tumors, its utility in detecting low grade tumors remains limited due to the lack of distinguishing cytological features between low grade disease and reactive processes. Currently there are several markers available or under investigation for the detection and monitoring/surveillance of bladder cancer, most of them have higher sensitivities, especially when used to identify low grade disease, but with lower specificities when compared to cytology. Furthermore, all of these tests must still be utilized in conjunction with cystoscopy findings.
Recently, cell-free DNA (cfDNA) isolated from urine supernatant has been shown to have great potential in bladder cancer detection and surveillance. Bladder cancer exhibits unique genetic features that can be identified from sequencing and expression of cfDNA.
Aim of study:
The aim of this study is to establish a method for a personalized urinary biomarker with the usage of well explored urothelail cancer genetic mutations in urine cfDNA, for the detection of bladder cancer presence.
Study Overview
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Ran Katz, MD
- Phone Number: +972-4-8629775
- Email: rank@ziv.gov.il
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age 18+ years old
- Able to give a written consent
- Able to provide a minimum of 60 mL of urine prior to undergoing transurethral resection of bladder tumor (TURBT)
- Presence of a bladder tumor
Exclusion Criteria:
- Active urinary infection
- Macro-hematuria
- Inadequate material for testing
- Benign bladder tumor
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence of somatic mutations in bladder tumor cells
Time Frame: 24 months
|
A set of selected somatic mutations will be checked against extracted urine cell free DNA from patients with bladder cancer, then a profile for each patient will be performed separately
|
24 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0121-21-ZIV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Neoplasm
-
Ikena OncologyBristol-Myers SquibbCompletedNeoplasms | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Bladder Cancer | Advanced Solid Tumor | Advanced Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | Bladder Disease | Solid Carcinoma | Neoplasm Malignant | Neoplasm, Bladder | Locally Advanced... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astellas Pharma Inc; Seagen...RecruitingStage III Bladder Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Metastatic Bladder Carcinoma | Urachal Adenocarcinoma | Locally Advanced Bladder Carcinoma | Malignant Renal Pelvis Neoplasm | Malignant Ureter Neoplasm | Malignant Urethral Neoplasm and other conditionsUnited States
-
Abdelwahab HashemUnknownTrauma | Bladder Cancer | Injuries | Bladder Urothelial Carcinoma | Perforation of Bladder | Recurrence Tumor | Resection Margin | Seeding, NeoplasmEgypt
-
Mansoura UniversityCompletedBladder Cancer | Bladder Disease | Bladder Neoplasm | Micro-RNAEgypt
-
Benha UniversityRecruiting
-
Betul KartalBağcılar Eğitim ve Araştırma HastanesiRecruiting
-
Diskapi Teaching and Research HospitalCompleted
-
Nektar TherapeuticsBristol-Myers SquibbCompletedNeoplasm Metastasis | Urinary Bladder NeoplasmUnited States, Spain, United Kingdom, Belgium, Canada, Australia, France, Italy, Greece, Germany, Portugal, Argentina, Israel, Russian Federation, Turkey, Mexico, Finland, Netherlands
-
GlaxoSmithKlineCompletedNeoplasms, Urinary BladderBelgium
-
Ziv HospitalAzrieli Faculty of medicine, Bar Ilan University, Safed, ILNot yet recruitingBladder Neoplasm
Clinical Trials on TURBT
-
Benha UniversityRecruiting
-
Gregers G HermannUnknown
-
Mansoura UniversityCompleted
-
Tribhuvan University, NepalCompletedObturator Jerk in TURBTNepal
-
Fundacio PuigvertKARL STORZ Endoscopy-America, Inc.RecruitingBladder Cancer | Urothelial Carcinoma BladderSpain
-
University of TriesteCompletedBladder Cancer | Non Muscle Invasive Bladder CancerItaly
-
Mansoura UniversityUnknown
-
University of California, IrvineNot yet recruitingMuscle-Invasive Bladder Cancer | Urothelial Bladder CancerUnited States
-
National Cancer Institute (NCI)Recruiting
-
Hospital Universitario de FuenlabradaRecruitingBladder Cancer | Urothelial Carcinoma Recurrent | Bladder Urothelial Carcinoma | Bladder Neoplasm | Bladder Cancer StageSpain